

# Antonio Piga

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11160344/publications.pdf>

Version: 2024-02-01

63  
papers

7,072  
citations

109311

35  
h-index

123420

61  
g-index

63  
all docs

63  
docs citations

63  
times ranked

3861  
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. <i>Haematologica</i> , 2004, 89, 1187-93.	3.5	772
2	A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. <i>Blood</i> , 2006, 107, 3455-3462.	1.4	636
3	SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJOR. <i>Lancet</i> , The, 1989, 334, 27-30.	13.7	520
4	Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. <i>Blood</i> , 2006, 107, 3738-3744.	1.4	424
5	Results of Long-Term Iron-Chelating Therapy. <i>Acta Haematologica</i> , 1996, 95, 26-36.	1.4	348
6	Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. <i>Blood</i> , 2006, 107, 3733-3737.	1.4	338
7	Survival and Disease Complications in Thalassemia Major. <i>Annals of the New York Academy of Sciences</i> , 1998, 850, 227-231.	3.8	312
8	Cardiovascular Function and Treatment in $\beta^2$ -Thalassemia Major. <i>Circulation</i> , 2013, 128, 281-308.	1.6	301
9	Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. <i>Blood</i> , 2003, 102, 1583-1587.	1.4	284
10	Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-year prospective study. <i>European Journal of Haematology</i> , 2008, 80, 168-176.	2.2	210
11	Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. <i>Haematologica</i> , 2006, 91, 873-80.	3.5	210
12	The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. <i>British Journal of Haematology</i> , 2002, 118, 330-336.	2.5	192
13	Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. <i>Haematologica</i> , 2008, 93, 741-752.	3.5	182
14	Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. <i>Blood</i> , 2011, 118, 884-893.	1.4	181
15	Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. <i>Blood</i> , 2002, 100, 1566-1569.	1.4	162
16	Hepatocellular carcinoma in the thalassaemia syndromes. <i>British Journal of Haematology</i> , 2004, 124, 114-117.	2.5	147
17	High nontransferrin bound iron levels and heart disease in thalassemia major. <i>American Journal of Hematology</i> , 2009, 84, 29-33.	4.1	128
18	Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: Results of a phase II pilot trial. <i>Movement Disorders</i> , 2011, 26, 1755-1759.	3.9	125

#	ARTICLE	IF	CITATIONS
19	Challenges of blood transfusions in $\beta^2$ -thalassemia. <i>Blood Reviews</i> , 2019, 37, 100588.	5.7	123
20	Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. <i>Haematologica</i> , 2006, 91, 1343-51.	3.5	109
21	Pregnancy and $\beta$ -thalassemia: an Italian multicenter experience. <i>Haematologica</i> , 2010, 95, 376-381.	3.5	103
22	Efficacy and safety of deferasirox doses of $\geq 30$ mg/kg per d in patients with transfusion-dependent anaemia and iron overload. <i>British Journal of Haematology</i> , 2009, 147, 752-759.	2.5	101
23	Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with $\beta^2$ -thalassaemia major: application of SQUID biomagnetic liver susceptometry. <i>British Journal of Haematology</i> , 2003, 121, 938-948.	2.5	100
24	A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in $\beta^2$ -thalassemia major (CORDELIA). <i>Blood</i> , 2014, 123, 1447-1454.	1.4	97
25	Hepatocellular carcinoma in thalassaemia: an update of the Italian Registry. <i>British Journal of Haematology</i> , 2014, 167, 121-126.	2.5	69
26	Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: results from the CORDELIA study. <i>European Journal of Haematology</i> , 2015, 95, 244-253.	2.2	61
27	Monitoring Long-Term Efficacy of Iron Chelation Treatment with Biomagnetic Liver Susceptometry. <i>Annals of the New York Academy of Sciences</i> , 2005, 1054, 350-357.	3.8	57
28	Amlodipine Reduces Cardiac Iron Overload in Patients with Thalassemia Major: A Pilot Trial. <i>American Journal of Medicine</i> , 2013, 126, 834-837.	1.5	51
29	Severe iron overload in Blackfan-Rosdahl anemia: A case-control study. <i>American Journal of Hematology</i> , 2009, 84, 729-732.	4.1	48
30	A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. <i>Blood</i> , 2012, 119, 3263-3268.	1.4	48
31	A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major. <i>Blood</i> , 2016, 128, 1555-1561.	1.4	47
32	Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine. <i>American Journal of Hematology</i> , 2015, 90, 91-96.	4.1	43
33	A Multi-Center Safety Trial of the Oral Iron Chelator Deferiprone. <i>Annals of the New York Academy of Sciences</i> , 1998, 850, 223-226.	3.8	42
34	Deferiprone. <i>Annals of the New York Academy of Sciences</i> , 2010, 1202, 75-78.	3.8	40
35	Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 428-435.	2.0	36
36	Purging iron from the heart. <i>British Journal of Haematology</i> , 2004, 125, 545-551.	2.5	34

#	ARTICLE	IF	CITATIONS
37	Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2011, 13, 34.	3.3	32
38	Changing patterns of splenectomy in transfusionâ€dependent thalassemia patients. <i>American Journal of Hematology</i> , 2011, 86, 808-810.	4.1	32
39	Current Status in Iron Chelation in Hemoglobinopathies. <i>Current Molecular Medicine</i> , 2008, 8, 663-674.	1.3	31
40	Assessment and management of iron overload in $\beta^2\alpha$ thalassaemia major patients during the 21st century: a realâ€life experience from the <sc>I</sc> <sc>W</sc> <sc>eb</sc> thal project. <i>British Journal of Haematology</i> , 2013, 161, 872-883.	2.5	31
41	Deferiprone therapy in homozygous human $\beta^2\alpha$ -thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity. <i>Translational Research</i> , 1999, 133, 64-69.	2.3	29
42	A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2012, 893-894, 127-133.	2.3	29
43	Deferasirox effect on renal haemodynamic parameters in patients with transfusionâ€dependent $\beta^2$ thalassaemia. <i>British Journal of Haematology</i> , 2015, 168, 882-890.	2.5	27
44	Late Effects of Bone Marrow Transplantation for Thalassemia. <i>Annals of the New York Academy of Sciences</i> , 1998, 850, 294-299.	3.8	19
45	A Phase II Study with ICL670 (Exjadeâ€), a Once-Daily Oral Iron Chelator, in Patients with Various Transfusion-Dependent Anemias and Iron Overload.. <i>Blood</i> , 2004, 104, 3193-3193.	1.4	17
46	Clinical management of cardiovascular complications in patients with thalassaemia major: a large observational multicenter study. <i>European Journal of Echocardiography</i> , 2011, 12, 242-246.	2.3	16
47	Role of pharmacogenetics on deferasirox AUC and efficacy. <i>Pharmacogenomics</i> , 2016, 17, 571-582.	1.3	15
48	Atrial fibrillation in $\beta^2$ -thalassemia Major Patients: Diagnosis, Management and Therapeutic Options. <i>Hemoglobin</i> , 2018, 42, 189-193.	0.8	15
49	Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. <i>Pharmacogenomics</i> , 2017, 18, 539-554.	1.3	14
50	Liver stiffness assessed by transient elastography in patients with $\beta^2$ thalassaemia major. <i>Annals of Hepatology</i> , 2016, 15, 410-417.	1.5	13
51	Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited. <i>Internal and Emergency Medicine</i> , 2019, 14, 365-370.	2.0	13
52	Once-Daily Treatment with the Oral Iron Chelator ICL670 (Exjadeâ€): Results of a Phase II Study in Pediatric Patients with $\beta^2$ -Thalassemia Major.. <i>Blood</i> , 2004, 104, 3614-3614.	1.4	11
53	Deferasirox pharmacokinetic and toxicity correlation in $\beta^2$ -thalassaemia major treatmentâ€. <i>Journal of Pharmacy and Pharmacology</i> , 2016, 68, 1417-1421.	2.4	9
54	Children of a lesser god or miracles? An emotional and behavioural profile of children born to mothers on dialysis in Italy: a multicentre nationwide study 2000â€12. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1193-1202.	0.7	8

#	ARTICLE	IF	CITATIONS
55	The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients. <i>Pharmacogenomics Journal</i> , 2019, 19, 417-427.	2.0	6
56	Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring. <i>Scientific Reports</i> , 2021, 11, 12581.	3.3	6
57	Deferasirox pharmacokinetic evaluation in $\hat{1}^2$ -thalassaemia paediatric patients. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 525-528.	2.4	5
58	Dual-Energy X-ray Absorptiometry Predictors of Vertebral Deformities in Beta-Thalassemia Major. <i>Journal of Clinical Densitometry</i> , 2018, 21, 507-516.	1.2	5
59	Clinical relevance of deferasirox trough levels in $\hat{1}^2$ thalassemia patients. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018, 45, 213-216.	1.9	3
60	The Influence of Cardiovascular Risk Factors and Hypogonadism on Cardiac Outcomes in an Aging Population of Beta-Thalassemia Patients. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 3.	1.6	3
61	Changing patterns of thalassaemia in Italy: a WebThal perspective. <i>Blood Transfusion</i> , 2021, 19, 261-268.	0.4	2
62	Agreement of liver iron quantification measurements with low Tc-SQUID biosusceptometers in Oakland, Torino and Hamburg. <i>International Congress Series</i> , 2007, 1300, 279-282.	0.2	0
63	Myocardial longitudinal strain as the first herald of cardiac impairment in very early iron overload state: an echocardiography and biosusceptometry study on beta-thalassemia patients. <i>American Journal of Cardiovascular Disease</i> , 2021, 11, 555-563.	0.5	0